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ABSTRACT: Background: An important challenge in
Parkinson’s disease research is how to measure disease
progression, ideally at the individual patient level. The
MDS-UPDRS, a clinical assessment of motor and non-
motor impairments, is widely used in longitudinal studies.
However, its ability to assess within-subject changes is
not well known. The objective of this study was to esti-
mate the reliability of the MDS-UPDRS when used to
measure within-subject changes in disease progression
under real-world conditions.
Methods: Data were obtained from the Parkinson’s Pro-
gression Markers Initiative cohort and included repeated
MDS-UPDRS measurements from 423 de novo Parkinson’s
disease patients (median follow-up: 54 months). Subtotals
were calculated for parts I, II, and III (in on and off states).
In addition, factor scores were extracted from each part.
A linear Gaussian state space model was used to differenti-
ate variance introduced by long-lasting changes from vari-
ance introduced by measurement error and short-term
ﬂuctuations. Based on this, we determined the within-
subject reliability of 1-year change scores.
Results: Overall, the within-subject reliability ranged from
0.13 to 0.62. Of the subscales, parts II and III (OFF) dem-
onstrated the highest within-subject reliability (both 0.50).
Of the factor scores, the scores related to gait/posture
(0.62), mobility (0.45), and rest tremor (0.43) showed the
most consistent behavior.
Conclusions: Our results highlight that MDS-UPDRS
change scores contain a substantial amount of error vari-
ance, underscoring the need for more reliable instru-
ments to forward our understanding of the heterogeneity
in PD progression. Focusing on gait and rest tremor may
be a promising approach for an early Parkinson’s disease
population. © 2019 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Interna-
tional Parkinson and Movement Disorder Society.
Key Words: disease progression; MDS-UPDRS; model-
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Parkinson’s disease (PD) is a chronic and progressive
neurodegenerative disease characterized by a heterogeneous
symptomatology involving both motor and nonmotor
impairments. There is a range of symptomatic treatments,
the efﬁcacy of which have been demonstrated at the
group level.1 An important area of research is the discov-
ery of novel strategies that may slow down or even halt
the neurodegenerative process.2 But perhaps the most
important development is the need to move toward per-
sonalized treatments, tailored to each patient’s individual
proﬁle and needs. Both developments require more ﬁne-
grained insights in progression of PD, ideally at the level
of individual patients, or at least tailored to a set of rec-
ognizable clinical proﬁles. Making individual prognostic
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predictions remains difﬁcult to date, both because of the
heterogenous symptomatology of PD and because we
lack objective biomarkers.
Recent longitudinal studies, both observational and
experimental, have primarily used the Movement Dis-
order Society — Uniﬁed Parkinson’s Disease Rating
Scale (MDS-UPDRS) to quantify disease progression.3,4
Introduced by the Movement Disorder Society in 2008
as a revision of the original UPDRS, it was designed as a
comprehensive instrument for evaluating both motor and
nonmotor impairments and disability in PD.5 The extent
to which the MDS-UPDRS, or in fact any instrument, is
suitable to quantify disease progression, strongly depends
on its reliability, that is, an instrument should show rea-
sonably low measurement error in comparison with
expected changes, so that the instrument can give a pre-
cise estimate of a patient’s true progression rate. Using
instruments with a high reliability allows for smaller sam-
ple sizes and shorter follow-up in trials assessing new
disease-modifying therapies.6 It is also a key prerequisite
to build ﬁne-grained predictive models.
A few aspects might affect the reliability of the MDS-
UPDRS with respect to monitoring changes over time.
First, the observer-rated items are subject to inter- and
intrarater variability. Second, an individual assessment
can only provide a snapshot of the patient’s condition
and is therefore prone to reﬂect short-term effects that
are irrelevant to the overall progression of the disease.
This is particularly relevant to the motor function
assessment (part III) as a substantial proportion of
patients experience motor ﬂuctuations as a consequence
of dopaminergic therapy (DT). To control for this, lon-
gitudinal studies often apply a washout period prior to
the motor assessment. However, this can be burden-
some for participants, and the length of the washout
period (commonly >6 or >12 hours) is not sufﬁcient to
cancel out the long duration response of levodopa and
dopamine agonists.7 In real-world applications, short-
term effects may also be introduced by factors such as
mood, stress, climate, time of the day, and, speciﬁcally
for parts I and II, whether the patient or caregiver
answered the questions.
Despite these sources of variation, the MDS-UPDRS
is often referred to as a highly valid and reliable instru-
ment, which is largely based on two studies examining
its clinimetric properties, one conducted by Goetz et al
in 2008 (English version) and the other by Martinez-
Martin et al in 2013 (Spanish version).5,8 Only the lat-
ter examined test-retest reliability, showing intraclass
coefﬁcients (ICCs) of greater than 0.90 for all subscales.
However, in the context of monitoring changes over
time, the high ICC values should be interpreted with
caution because these values only reﬂect how well the
scale can differentiate between patients at a given point,
that is, it is a ratio between the true variance of abso-
lute scores and the total variance of absolute scores
(consisting of the true variance and variance produced
by measurement error).9 To quantify the scale’s ability
to assess changes over time, we need a measure of reli-
ability that incorporates the variance of the within-
subject changes instead.
The problem becomes apparent when looking at two
subsequent 1-year change scores of the MDS-UPDRS in
the Parkinson’s Progression Markers Initiative (PPMI)
cohort (Fig. 1). A clear negative correlation can be seen,
which means that if a MDS-UPDRS score increases
during 1 period, it is likely to decrease in the subse-
quent period, and vice versa. This behavior is in essence
a reﬂection of the well-known “regression toward the
mean” phenomenon, indicating that the observed
changes include a substantial amount of measurement
error and are only partly related to changes in the true
disease state. These effects can be quantiﬁed using
models that assume there is an underlying “true” latent
phenotype that evolves over time, of which the instru-
ment provides noisy estimates at different times.
Study Objective
The objective of this study was to use data from a
large cohort study to provide a realistic estimate of the
reliability of the MDS-UPDRS when used to measure
individual changes in disease progression. By modeling
time series of MDS-UPDRS scores using linear state
space models, we aimed to discriminate between
FIG. 1. Correlation between two subsequent 1-year change scores of
the MDS-UPDRS part III (OFF) on the PPMI data set. Line is ﬁtted by lin-
ear regression on the response variable y3-y2. A similar negative corre-
lation can be seen in parts I, II, and III (ON).
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variance introduced by actual disease progression and
variance introduced by “noise,” consisting of measure-




The data set used here was obtained from the PPMI
database (www.ppmi-info.org/data). For up-to-date
information on the study, please visit www.ppmi-info.
org. A detailed description of the study design has been
published elsewhere.10 In brief, PPMI is a multicenter
cohort study designed to identify PD progression bio-
markers, which was launched in June 2010. Data used
here consisted of the MDS-UPDRS measurements from
all included PD subjects and were downloaded from the
study website on June 27, 2017.
All sites underwent web-based and in-person training
in conducting the MDS-UPDRS.10 The complete MDS-
UPDRS was administered at 3-month intervals during
the ﬁrst year of participation and every 6 months there-
after, up to 5 years after inclusion. We used all avail-
able measurements from parts I and II. For part III, we
included all annual measurements, because only during
these visits did the protocol included scripted OFF state
assessments (deﬁned as >6 hours postdose or not receiv-
ing any dopaminergic therapy). By also including non-
annual visits, we would have introduced bias because
these visits only contained OFF assessments from subjects
without dopaminergic therapy. It should be noted that
the screening visit 1 month before baseline was included,
because per protocol no participants were on dopaminer-
gic therapy at inclusion (ie, all assessments could be classi-
ﬁed as OFF). At annual visits, part III was repeated
approximately 1 hour postdose for subjects receiving
dopaminergic therapy. These assessments were classiﬁed
as ON if performed <6 hours postdose. Part IV was not
included in our analysis because it focuses on side effects
of dopaminergic therapy and is therefore less suitable for
monitoring disease progression.
Subscale scores were computed for parts I, II, and III sep-
arately by summing the scores of all containing items.5 In
addition, we performed a factor analysis separately for
parts I, II, and III using all longitudinal MDS-UPDRS
scores that were also included in the other analyses. Factor
loadings were computed using the principal component
method for parameter estimation, followed by varimax
rotation. The decision on the number of factors to retain
was determined visually based on the location of the elbow
in the scree plot. To compute the factor scores, we summed
all items weighted by their factor loadings. The meaning
assigned to the identiﬁed factors was based on the items
with the highest loading. In the analysis, all subscale and
factor scores were treated as continuous variables.
MDS-UPDRS Progression Model
Observational data sets containing time series can be
used to model the measurement error of an instrument
using linear state space models.11 In this study, a linear
Gaussian state space model was used to describe the
within-subject changes in MDS-UPDRS scores over
time, deﬁned by the following 2 equations:
yt, i = θt, i + vt, i vt, iN 0,σ2E
  ð1Þ
θt, i = θt−1, i +wt, i wt, iN trend,σ2ΔT
  ð2Þ
Time is indicated by the discrete index t which refers
to the number of months after screening. Months with-
out measurements in between study visits were treated as
missing values. The index i refers to an individual subject
in the study sample. In equation (1), the observation
equation, analogous to classical test theory, we assume
that there are hidden true progression states θt,i, which
can only be measured indirectly through our observa-
tions yt,i, the MDS-UPDRS scores. These observations
are the result of the true progression states θt,i plus
Gaussian noise vt,i (independent and identically distrib-
uted with mean 0 and variance σ2E). Thus, in our model
σ2E is closely related to measurement error, reﬂecting
both inter- and intrarater variability and short-term
effects that are irrelevant to disease progression. These
effects may be introduced by a wide range of factors
such as mood, stress, and climate at the time of the
assessment. In equation (2), the state equation, we
assume that the true progression states θt,i from adja-
cent study visits are linked through Gaussian true pro-
gression wt,i (independent and identically distributed
with mean trend and variance σ2ΔT). Therefore, σ
2
ΔT cor-
responds to the true variance of change scores.
Although factors such as age inﬂuence the rate of pro-
gression, these were not included in our model because
we aimed to estimate the magnitude of the variance in
true progression σ2ΔT , not which factors explain this
variance. Several Markov assumptions are implied by
the model, for instance, given the previous state θt− 1,i
the present state θt,i is independent of all other past
states, and the observed score only depends on the cur-
rent hidden state. We estimate one trend parameter for
the study population, independent of the time t or indi-
vidual i. This implies that we assume that the average
progression in the study population is linear. Given the
observed progression of the subscales of the MDS-
UPDRS as displayed in Figure 2 and in the Supplementary
Materials, this appears to be a reasonable assumption.
Individual progression is not necessarily linear, becausewt,
i allows for individual variation to the population average
trend. The speciﬁcation of the model is completed by
deﬁning the initial state θ0,i, which is assumed to be
1482 Movement Disorders, Vol. 34, No. 10, 2019
E V E R S E T A L
normally distributed with mean m0 and variance C0.
These parameters can be estimated without observations
at this point using the distribution of the scores at the ﬁrst
point and the assumption of a constant average progres-
sion of the study population. See Figure 3 for a graphical
representation of the model used in this study.
Estimation and Validation of Model Parameters
The model parameters were estimated using maxi-
mum likelihood estimation, implemented in R using the
dlm package dedicated to linear state space models.12
For replication purposes, we should note that there is
no direct option in the dlm package to add a trend.
To achieve this, we introduced a second variable to
the hidden states that is set to a constant. So, in our
implementation, θt,i is a vector of length 2, with the ﬁrst
element representing the disease progression state and
the second element a constant 1. By properly setting the
transition matrix G and the variance of wt,i, we can keep
this variable constant while having the new hidden state
depend on the trend (which is a value in G): θt,i =
Gθt − 1,i + wt,i. Conﬁdence intervals were calculated
using the simple percentile bootstrap method with 1000
repeats: we randomly sampled patients with replace-
ment to construct bootstrap samples and used the 2.5%
and 97.5% percentiles of the estimates to obtain 95%
conﬁdence intervals. The appropriateness of the model
to describe the data was assessed by evaluating the dis-
tribution of residuals, that is, the difference between the
FIG. 2. Left: number of assessments included in the analysis for each part and on each visit. Middle: progression of the subscales on a group level
(median, 10%, and 25% around the median are shown; missing values were excluded). Right: illustration of the individual progression of the subscale
scores (8 illustrative examples of cases with <2 missing values are shown).
FIG. 3. Graphical presentation of the MDS-UPDRS progression model, as applied to each individual subject denoted by the indices i.
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estimated true progression states and the observed
values and the difference between the predicted next
state and its measurement.
Based on the estimated parameters, the within-subject











Here, σ^2ΔT denotes the estimate of the true variance of
change scores, which is divided by the total variance of
1-year change scores σ^2ΔX, consisting of the true vari-
ance plus 2 times the variance produced by measure-
ment error σ^2E.
In addition, the effect of the length of the levodopa
washout period on part III OFF measurements was
assessed by comparing the estimates for two different
thresholds. Because the median time after DT (for partici-
pants receiving DT) was approximately 14 hours, we
compared the original threshold (>6 hours postdose) with
the threshold >14 hours postdose. To maximize the power
of the comparison, we ﬁrst generated the bootstrap sam-
ple before applying the two different thresholds.
Results
A total of 423 PD subjects were included (277 men
and 146 women). At baseline, the average age was
61.7 years, and the average time since diagnosis was
7 months (see Table 1 for all baseline characteristics).
The maximum follow-up period was 60 months. In
Figure 2 (left), the number of included assessments can
be seen for each visit and for each part of the MDS-
UPDRS. The attrition in the number of included parts I
and II assessments was almost completely because of
loss to follow-up. The main reason why fewer part III
OFF than parts I and II assessments were included for
the annual visits is that not all part III OFF assessments
fulﬁlled the >6 hours postdose criterion. For each part
of the MDS-UPDRS, the progression at the group level
and an illustration of individual progression patterns is
displayed in Figure 2 (middle and right).
In part I, three factors were identiﬁed (combined
explained variance of 46.4%), corresponding to affective
symptoms (F1.2), cognitive symptoms (F1.3), and other
nonmotor symptoms (F1.1). Also, from part 2 three fac-
tors were extracted (combined explained variance of
54%), largely corresponding to impairments in mobility
(F2.1), drooling, swallowing and speech (F2.2), and
tremor (F2.3). Last, seven factors were identiﬁed in part
III (with a total explained variance of 62.5%),
corresponding to bradykinesia in left extremities (F1),
bradykinesia in right extremities (F2), postural instabil-
ity and gait difﬁculty (F3), rest tremor (F4), rigidity
(F5), facial expression, speech and global bradykinesia
(F6), and postural and kinetic tremors (F7); for details
see Supplementary Materials. These results are similar
but not identical to the factor structure identiﬁed by
Goetz et al.5
MDS-UPDRS Progression Model
The estimations of the parameters σ2E, σ
2
ΔT , trend, and
within-subject reliability, including their 95% conﬁ-
dence interval, are presented in Table 2. Within-subject
reliability varied from 0.13 to 0.62 for the different
subscales and factors. Of all subscales, parts II and III
(OFF) demonstrated the highest within-subject reliabil-
ity. Factor 3.3 (postural instability and gait difﬁculty),
2.1 (mobility), and 3.4 (rest tremor) were the most reli-
able factor scores.
Regarding the part III subscale (OFF), σ^2E was signiﬁ-
cantly lower (difference of –1.75; 95% CI: –2.81 to
–0.84), and the within-person reliability was signiﬁ-
cantly higher (difference of 0.04; 95% CI: 0.01–0.07)
when applying the >14-hour threshold in comparison
with the >6-hour threshold (P < 0.001 based on boot-
strap procedure). We should note that because the time
since last medication intake was not randomized in this
data set, the possibility of confounding should be con-
sidered (see Supplementary Materials).
Model Performance
The QQ plots of parts I and II displaying the model
residuals showed heavier tails than the normal distribu-
tion, which could be a consequence of both vt,i and/or
wt,i having a distribution with heavier tails than the
normal distribution (see Supplementary Materials).
There were no indications that the data set contained
any outliers that might have been caused by erroneous
data entry (eg, no values were out of range of feasible
MDS-UPDRS scores), so all data were retained. The
distribution of residuals from part III more closely
resembled the normal distribution. The inverse
TABLE 1. Baseline characteristics of the study sample
(n = 423)
Mean/percentage SD Range
Age (years) 61.7 9.7 33.5–84.8
Sex (% men) 65.5 % - -
Time since diagnosis of PD (months) 7 0.05 0–36
Hoehn & Yahr (% within group)
Stage 1 49.2 % - -
Stage 2 50.8 % - -
MDS-UPDRS
Part I 5.8 4.2 0–22
Part II 5.7 4.2 0–24
Part III (OFF) 20.3 8.9 3–60
Modiﬁed Schwab & England 93.9 5.9 70–100
Years of education 15.5 3.0 5–26
Montreal Cognitive Assessment 27.1 2.3 17–30
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correlation between 2 subsequent 1-year change scores
that was presented earlier was similar in data generated
based on the model and estimated parameters (see Sup-
plementary Materials).
Discussion
Our primary aim was to assess the reliability of the
MDS-UPDRS as a tool to measure individual disease pro-
gression over time in a population of early-stage PD
patients. A linear Gaussian state space model was applied
to a large observational data set to capture the longitudi-
nal behavior of the different subscales and factors. The
selected model is closely related to classical test theory,
which was the theoretical foundation for previous esti-
mates of the (test-retest) reliability of the MDS-UPRS.9
The novelty of applying this model to time series of
MDS-UPDRS measurements lies in its ability to provide
estimates for both the variance introduced by “noise” (ie,
measurement error and short-term effects) and the vari-
ance introduced by long-lasting differences in individual
progression rates. Expanding on previous validation stud-
ies, which presented a high between-subject reliability for
all parts of the MDS-UPDRS,8 we now demonstrate that
the within-subject reliability of all parts is noticeably
lower. Parts II and III (OFF) demonstrate a favorable
within-subject reliability compared with parts I and III
(ON). The factors related to mobility and tremor demon-
strated a relatively consistent behavior and may be, in
terms of their reliability, most suitable to monitor
individual disease progression in early PD. Last, our
ﬁndings underscore the importance of considering the
symptomatic effects of levodopa when using part III to
monitor changes over time, as OFF assessments >6 hours
postdose were more consistent than ON assessments,
and a longer washout (>14 hours) may further increase
the assessment’s reliability.
Like any model, ours is a simpliﬁcation of reality and
does not aim to explain the complete behavior of the
MDS-UPDRS, but rather attempts to capture aspects rel-
evant to the question at hand. Still, it is important to
explore the assumptions underlying the model and their
effect on the relevance of the results. First, some devia-
tions from normality were observed, mostly visible in
parts I and II. Although using a distribution with heavier
tails might have produced a more accurate ﬁt to the
data, it also would have increased the model’s com-
plexity, affecting both the complexity of the parame-
ter estimation algorithm and the interpretation of its
results.13 Given that data sampled from our model
and real data display a similar negative correlation
between two subsequent change scores, we believe the
model is an appropriate choice to capture this remark-
able behavior of the MDS-UPDRS. Second, it was
assumed that both σ2E and σ
2
ΔT would remain constant
during the course of the disease, which is a simpliﬁca-
tion; it is reasonable that, for example, the error variance
(σ2E) of part III is larger in populations with a longer dis-
ease duration with more severe and unpredictable motor
ﬂuctuations. Also, some nonmotor symptoms start to
TABLE 2. Estimated parameters of the linear state space model, displayed as the estimate on the whole data set and 95%






I 4.87 (4.41–5.42) 4.22 (3.35–5.17) 0.92 (0.82–1.02) 0.30 (0.25–0.36)
II 3.66 (3.15–4.19) 7.22 (5.96–8.52) 1.03 (0.91–1.16) 0.50 (0.43–0.56)
III (OFF) 15.52 (12.16–19.24) 31.13 (24.14–38.73) 2.63 (2.34–2.94) 0.50 (0.40–0.60)
III (ON) 27.07 (17.22–35.66) 16.15 (7.44–36.14) 1.04 (0.55–1.48) 0.23 (0.10–0.43)
Factors part I
F1.1 (other nonmotor) 0.29 (0.26–0.32) 0.15 (0.12–0.17) 0.15 (0.13–0.17) 0.20 (0.17–0.24)
F1.2 (affective symptoms) 0.41 (0.35–0.47) 0.16 (0.11–0.21) 0.03 (0.01–0.05) 0.16 (0.11–0.22)
F1.3 (cognitive symptoms) 0.30 (0.25–0.35) 0.26 (0.16–0.39) 0.13 (0.10–0.16) 0.30 (0.20–0.43)
Factors part II
F2.1 (mobility) 0.16 (0.14–0.19) 0.27 (0.22–0.34) 0.17 (0.15–0.20) 0.45 (0.38–0.53)
F2.2 (swallowing, speech) 0.23 (0.20–0.25) 0.15 (0.12–0.19) 0.09 (0.07–0.11) 0.25 (0.21–0.31)
F2.3 (tremor) 0.28 (0.26–0.31) 0.21 (0.17–0.26) 0.02 (0.00–0.04) 0.27 (0.22–0.32)
Factors part III (OFF)
F3.1 (bradykinesia left) 0.14 (0.11–0.16) 0.10 (0.08–0.13) 0.11 (0.09–0.14) 0.27 (0.20–0.35)
F3.2 (bradykinesia right) 0.22 (0.17–0.27) 0.13 (0.08–0.18) 0.11 (0.08–0.13) 0.23 (0.14–0.33)
F3.3 (gait and posture) 0.11 (0.08–0.14) 0.35 (0.19–0.51) 0.10 (0.07–0.14) 0.62 (0.44–0.75)
F3.4 (rest tremor) 0.19 (0.15–0.23) 0.28 (0.20–0.37) 0.10 (0.08–0.13) 0.43 0.33–0.54)
F3.5 (rigidity) 0.26 (0.21–0.30) 0.17 (0.12–0.23) 0.08 (0.05–0.11) 0.25 (0.18–0.34)
F3.6 (other bradykinesia) 0.29 (0.25–0.34) 0.10 (0.07–0.14) 0.05 (0.03–0.08) 0.15 (0.09–0.21)
F3.7 (other tremor) 0.43 (0.36–0.49) 0.13 (0.08–0.19) -0.01 (-0.04 to 0.01) 0.13 (0.08–0.19)
σ^2E, error variance; σ^
2
ΔT , variance in true scores; r^ΔΔ, within-subject reliability.
aBoth σ^2ΔT and the dtrend and therefore also r^ΔΔ are dependent on the length of the interval. Values here are presented for a follow-up period of 1 year.
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develop later in the disease, which would result in a
higher true progression variance (σ2ΔT) of part I in this
population. Although subjects with de novo PD are
often the population of interest in cohort studies on dis-
ease progression, the generalizability to other disease
stages remains to be evaluated. Given the homogeneity
of the PPMI cohort in terms of disease duration at study
start and the maximum follow-up of only 5 years, we
believe it was reasonable to estimate one set of variance
components that describes the behavior of the MDS-
UPDRS in early PD. This is supported by the observa-
tion that the mean and variance of yearly changes did
not show any obvious changes over time during the
follow-up period (see Supplementary Materials). Third,
the interpretation of the model parameter σ2ΔT deserves
some nuance. Although σ2ΔT was referred to as variance
in true progression, a more accurate description would
be variance in long-term changes in PD symptomatol-
ogy. Both the underlying disease progression and long-
term effects of symptomatic treatment (for example, the
effect of treatment with antidepressants on part I scores
or the gradually increasing dose of dopaminergic medi-
cation on parts II and III scores) may contribute to this
parameter. Future work may aim to disentangle the
contributions from both factors. Last, results presented
here are based on one cohort. Although statistical pro-
cedures were used to estimate the conﬁdence intervals
of the estimations, the results should be validated on
independent cohorts.
An important advantage of our approach is that the
estimates are based on the actual results from a large
multicenter cohort study with all its logistical challenges,
in contrast with the highly standardized conditions in
which most clinimetric validation studies take place (eg, a
small number of participating study centers, a small num-
ber of assessors and a short time interval between test
and retest, so short-term effects are more likely to be sim-
ilar during both). Therefore, our results are more likely
to reﬂect the real-world behavior of the MDS-UPDRS
when used in this type of study. The presented within-
subject reliabilities can be interpreted as the proportion
of variance in MDS-UPDRS change scores that originate
from long-lasting changes in PD symptomatology and
are therefore directly relevant to any cohort study aiming
to build predictive models for disease progression.
Indeed, the identiﬁed behavior of the MDS-UPDRS may
well be an explanation for the results of Latourelle et al,
who achieved a higher explained variance (Pearson R2)
when modeling part III changes in untreated subjects
compared with part III (ON) changes in subject receiving
DT.14 Because error variance is a substantial proportion
of variance in all MDS-UPDRS change scores, the
explained variance that can be maximally achieved is
limited, and researchers should be aware of the risk of
overﬁtting complex predictive models. It should be noted
that it is possible, for example in the case of performing
regression on the change scores, to reach a higher
explained variance than the presented within-subject reli-
abilities by including the baseline score or the previous
change score in the model (such as shown in Fig. 1).
However, what happens here is that a part of the error
variance (σ2E) is explained in the model, which does not
provide any knowledge about the actual disease pro-
gression (σ2ΔT). The results should also be taken into
account when applying (parts of) the MDS-UPDRS for
individual follow-up in clinical practice, because the lit-
erature suggests that changes smaller than the measure-
ment error (σE), of which we provide estimates, are
unlikely to be clinically meaningful.15
Although the developers of the MDS-UPDRS already
recommended analyzing the subscales separately instead
of analyzing one composite MDS-UPDRS score, this
study allows for a more informed selection of factors
and subscales based on their reliability. It deserves some
attention that the factor scores related to gait/mobility
and rest tremor outperformed the factor scores related to
bradykinesia, rigidity, kinetic/postural tremor, and
nonmotor symptoms. Initial studies suggested that rest
tremor severity measured by the UPDRS did not corre-
late with disease duration and was therefore not a good
marker for progression.16,17 However, these studies were
all performed in populations with a baseline disease
duration of 4–9 years, and later evidence suggested that
resting tremor severity does worsen in the early stages of
the disease.18 Our ﬁndings support this and show that,
compared with other items (eg, bradykinesia and rigid-
ity), the items related to resting tremor are a relatively
reliable way to measure the variation in within-subject
changes of symptom severity in early PD. Although
detailed studies on the progression of gait and balance
impairments in early PD are rare, Galna et al showed
that in this population a deterioration in gait impair-
ment can be observed within 18 months of follow-
up.19 In addition, there are indications that early changes
in gait/mobility are measurable using the Timed Up &
Go test.20 We also observed signiﬁcant progression in
gait/posture-related items of the MDS-UPDRS in early
PD and demonstrated a relatively consistent behavior of
these items over time. The latter may be partially
explained by the contribution from nondopaminergic
pathology, which renders these items less sensitive to the
short-term effects of DT.18
In conclusion, our results support the search for more
reliable instruments to monitor individual changes in PD
symptomatology. In this light, wearable sensors have
the potential to overcome some limitations of the MDS-
UPDRS by collecting rater-independent and continuous
data in the patient’s own natural environment.21 The
ﬁnding that gait/mobility and tremor-related items dem-
onstrate the highest within-subject reliability, highlights
1486 Movement Disorders, Vol. 34, No. 10, 2019
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the potential of sensor-based outcome measures in these
domains.22-25 Hopefully, the combination of optimally
using current clinical rating scales and the development
of new reliable instruments will lead to a better under-
standing of the large heterogeneity in PD progression
and pave the way for reliable measures of new disease-
modifying treatments.
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